Evaluating the Clinical Generalizability of FDA-Approved AI-Enabled Medical Devices: Insights and Implications
Highlight
AI-enabled medical devices have rapidly expanded, especially in radiology and cardiovascular specialties, but only about half present clinical performance data at FDA approval.
Less than one-third of clinical studies report sex-specific or age-specific data, limiting insights on device applicability across diverse populations.
Retrospective designs dominate device validation, with prospective and randomized trials remaining rare, raising questions about robustness of evidence.
The scarcity of detailed development and performance data highlights significant gaps in assessing the clinical generalizability of these devices.
Study Background and Disease Burden
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.